Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on the day's biggest business stories
Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Sign up for Axios NW Arkansas
Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters
A scientist working during at the Oxford Vaccine Group's laboratory facility at the Churchill Hospital in Oxford, England, in June. Photo: Steve Parsons/Pool/AFP via Getty Images
The University of Oxford announced Monday that a COVID-19 vaccine it's developed with AstraZeneca is 70.4% effective in preventing people from developing symptoms, per interim data from Phase 3 trials.
Why it matters: The Oxford-AstraZeneca vaccine is shown to work in different age groups and can be stored at fridge temperature. It is much cheaper than other vaccines in development and is part of the global COVAX initiative, designed to ensure doses go where they're most needed.
- AstraZeneca CEO Pascal Soriot said in a statement that the vaccine's "simple supply chain and our no-profit pledge and commitment to broad, equitable and timely access means it will be affordable and globally available, supplying hundreds of millions of doses on approval."
Between the lines: The findings come from combining results from two different dosing regimes.
- When two full doses were given to volunteers at least a month apart, the efficacy was 62%. This rose to 90% among those given half a dose, followed by a full one, the university noted in a statement.
- Pfizer and Moderna both reported earlier this month their coronavirus vaccines had efficacy rates of about 95%.
Yes, but: The Food and Drug Administration initially set the bar for a COVID-19 vaccine to be 50% effective, roughly in line with the seasonal flu vaccine. A 70% efficacy was a best-case scenario back then, per Axios' Marisa Fernandez.
For the record: More than 24,000 volunteers were involved in the trials in the U.K., Brazil and South Africa — including 131 coronavirus cases, per the university.
- There were no hospitalizations nor severe cases of COVID-19 reported from participants treated with the vaccine.
What to expect: The university said in a statement scientists are "hoping to supply 3 billion doses of the vaccine and make it available to people around the world by the end of next year."
Flashback: Oxford University coronavirus vaccine trials show strong immune response
Editor's note: This article has been updated with new details throughout.